Welcome to our dedicated page for Maravai Lifesciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai Lifesciences Holdings stock.
Maravai Lifesciences Holdings Inc. (MRVI) provides essential tools for breakthrough therapies and diagnostics through its nucleic acid production and biologics safety testing solutions. This news hub offers investors and industry professionals direct access to verified updates about the company's scientific advancements and strategic developments.
Track MRVI's latest financial results, manufacturing innovations, and partnership announcements in one centralized location. Our curated news collection helps stakeholders monitor regulatory milestones, technology licensing agreements, and capacity expansion initiatives critical to the life sciences sector.
Key updates include earnings disclosures, facility certifications, reagent production scaling efforts, and quality control advancements. Users will find information about Maravai's GMP-grade oligonucleotides, CLIA-certified testing services, and contributions to cell/gene therapy development pipelines.
Bookmark this page for real-time access to Maravai's progress in enabling precision medicine and vaccine development. Check regularly for objective reporting on their role in supporting biopharmaceutical research and diagnostic innovation worldwide.
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) reported Q1 2024 financial results with revenue of $64.2 million, a net loss of $(22.7) million, and adjusted EBITDA of $7.8 million. The company reaffirmed its full-year 2024 revenue guidance of $265.0 million to $285.0 million. Maravai highlighted partnerships with Lonza and Alphazyme, new product launches, and facility expansions. The company received industry recognition for innovation. Despite a 19% revenue decrease YoY, Maravai remains focused on growth and delivering value to customers.
TriLink BioTechnologies, a Maravai LifeSciences company, has entered into a non-exclusive License and Supply Agreement with Lonza for its CleanCap mRNA capping technology. This agreement will allow Lonza to use TriLink's patented cap analogs for mRNA development and manufacturing services, enhancing the accessibility of CleanCap technology in the industry. CleanCap technology offers high capping efficiency and streamlines mRNA production processes, contributing to improved mRNA function and increased capped material yield.
FAQ
What is the current stock price of Maravai Lifesciences Holdings (MRVI)?
What is the market cap of Maravai Lifesciences Holdings (MRVI)?
